Archive: November 2017

Real-World Use of Scalp Cooling to Reduce Chemotherapy-Related Hair Loss 

Hope S. Rugo, MD

  H&O  How long has scalp cooling been in use as a method to reduce hair loss during chemotherapy? HR  Scalp cooling involves the use of […]

Immunotherapy in Ovarian Cancer: Where Are We Now, and Where Are We Going? 

Amir Anthony Jazaeri, MD

  H&O  What types of immunotherapy have been investigated for use in women with ovarian cancer? AJ  The 3 broad areas of immunotherapy that have been […]

A Mind Map for Managing Minimal Residual Disease in Acute Myeloid Leukemia

Christopher B. Benton, MD, and Farhad Ravandi, MD

  Abstract: Advances in detecting traces of leukemia that were previously unidentifiable have increasingly led to the incorporation of information about residual disease into clinical decision […]

The Effect of Novel Therapies in High-Molecular-Risk Multiple Myeloma

Guido Lancman, MD, Douglas Tremblay, MD, Kevin Barley, MD, Bart Barlogie, MD, PhD, Hearn Jay Cho, MD, PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Erin Moshier, MS, Samir Parekh, MD, and Ajai Chari, MD

  Abstract:  Multiple myeloma is a heterogeneous disease with a prognosis that varies with patient factors, disease burden, tumor biology, and treatments. Certain molecular abnormalities confer […]

New Guidelines From the NCCN for Polycythemia Vera

Ruben A. Mesa, MD

  H&O  What is polycythemia vera? RM  Polycythemia vera is a myeloproliferative neo­plasm. There are approximately 150,000 patients with poly­cythemia vera in the United States. The […]

Patient-Derived Tumor Xenograft Models in Drug Development

Manuel Hidalgo, MD, PhD

  H&O  What types of preclinical models are used to predict clinical activity of novel therapies in cancer patients? MH  There are now 4 types of […]

Advances in the Management of Fungal Infections

Matthew W. McCarthy, MD

  H&O  What are the most common fungal infections among patients with hematologic malignancies? MM We are increasingly forced to confront this issue because some treatments […]

Hem/Onc News

Devon Schuyler

Abemaciclib Approved in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer On September 28, the US Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Lilly) as a […]

Letter From the Editor: In Memory of Oliver Press, MD, PhD

Brad S. Kahl, MD

We have lost a giant. For those of us who knew and worked with Oliver Press, it feels like a punch in the gut. Some individuals […]

Back to Archive